完成了$ 102M系列D轮的HistoSonics, 推进非侵入性肝癌治疗平台. HistoSonics completes $102M Series D round to advance non-invasive liver tumor treatment platform.

医疗科技公司HistoSonics完成了1.02亿美元的D轮融资, 用资金推进其非侵入性组织瘤治疗平台. HistoSonics, a medical tech company, has completed a $102M Series D round, using funds to advance its non-invasive histotripsy treatment platforms. 其爱迪生系统使用聚焦超声波来瞄准肝肿瘤,提供手术、辐射和化疗的替代办法。 Its Edison system uses focused ultrasound to target liver tumors, offering an alternative to surgeries, radiation, and chemotherapy. 这项投资将加速该公司的美国和全球增长,并支持该公司的BOOMBOX总研究,评价爱迪生肝肿瘤治疗系统。 The investment will accelerate the company's U.S. and global growth and support its BOOMBOX master study evaluating the Edison system for liver tumor treatment.